GBT - Grupo Biotoscana, is a leading biopharmaceutical company in Latin America with a truly pan-regional presence and focus on specialty pharmaceuticals. GBT has revenue of US$250 million, with operating companies in 10 countries throughout Latin America and a strong combination of world-class licensed products and proprietary specialty branded generic products. The company operates under the Biotoscana, United Medical and LKM brands and focuses on rapidly-growing market segments, such as oncology, infectious diseases, hematology, genetic disorders, HIV and rare diseases.